1 / 13

Preclinical Guidelines: Development of Radioprotective / Mitigative Agents

Preclinical Guidelines: Development of Radioprotective / Mitigative Agents. Julie L. Ryan, PhD, MPH. Departments of Dermatology & Radiation Oncology University of Rochester Medical Center Rochester, New York, USA. Radioprotector / Mitigator Development Program. Primary Objective:.

aunderwood
Download Presentation

Preclinical Guidelines: Development of Radioprotective / Mitigative Agents

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Julie L. Ryan, PhD, MPH Departments of Dermatology & Radiation Oncology University of Rochester Medical Center Rochester, New York, USA

  2. Radioprotector/Mitigator Development Program Primary Objective: Development of agents which selectively protect normal tissues (NOT tumors) against radiation. Secondary Objective: Development of these agents will improve patient quality of life through the prevention and/or reduction of radiation treatment-related toxicities.

  3. Radioprotector/Mitigator Development Program Radiation Protectors:Agents given before radiation exposure to prevent or reduce damage to normal tissues. Radiation Mitigators:Agents given after radiation exposure but before symptoms occur with the intention of preventing or reducing damage to normal tissues. Radiation Treatments:Agents given after radiation exposure and after symptoms occur with the intention of reducing damage to normal tissues. Regardless of time of administration Program will develop agents that most effectively protect normal tissues, NOT tumors, against radiation exposure.

  4. Preclinical Guidelines Selection Stage I: Toxicity & Maximum Tolerated Dose Stage II: Radiation Protection/Mitigation Activity Stage III: Drug Evaluation, Production & Formulation for Clinical Trials.

  5. Selection of Candidate Agents (NIAID’s CMCR, drug companies, CTEP, independent labs, etc) Candidate Agent MUST satisfy one or more of the following criteria: General protection /mitigation/rescue of normal tissue from radiation damage. Protect ion/mitigation/rescue of specific normal tissue from radiation damage. Does NOT protect tumors from radiation.

  6. Stage I: Toxicity & Maximum Tolerated Dose Maximum Tolerated Dose (MTD) Single Dose Multiple Repeated Dose MTD Determined Toxicities Reviewed Pharmacokinetics/Levels in Plasma No Toxicities Acceptable Toxicities Unacceptable toxicities NFT

  7. Stage II: Radiation Protection/Mitigation Activity Protection of Normal Tissues Protection of Tumors Biological Mechanism of Action

  8. Stage II: Radiation Protection/Mitigation Activity Normal Tissue Protection Tumor Protection In vitro (clonogenic) In vivo (xenograft) Decision YES for at least one organ; Bone Marrow Skin Gut Lung CNS/Brain N Y Y N N N Y Y GO GO NFT NFT

  9. Stage II: Radiation Protection/Mitigation Activity Biological Mechanism (Normal Tissue Protection) No Yes More in vitro/in vivo testing Proceed with continued mechanistic studies

  10. Stage III: Drug Evaluation, Production & Formulation for Clinical Trials • Must know the following: • Preliminary toxicity profile (MTD or NOEAL) • Degree, duration, and scope of protection of normal tissues • Biological activity & mechanism (normal tissue protection) • Bioavailability via intended route of administration • Duration & degree of exclusion of drug from tumor • Concentration ratios: plasma/normal tissue/tumor • Toxicity in non-tumor-bearing rodents • Suitable dose formulation (pharmacological data) • Feasibility for large scale production

  11. Stage III: Drug Evaluation, Production & Formulation for Clinical Trials OPTIONAL: Combination Treatment Evaluation: • Test for multi-organ protection using combination of promising candidate agents. • Combination treatments evaluated for toxicities & lack of protection of normal tissue. • Potential Issue: Agent may protect one type of normal tissue from radiation damage but could sensitize another type of normal tissue.

  12. Discussion What are the minimal, acceptable and preferred procedures & guidelines? • 50% reduction in radiation toxicity for specified organ (i.e., normal tissue). • Must use clonogenic assays for survival  MTT assays are unacceptable (NCI-60 tumor panel not required). • Clonogenic assays performed on 2 relevant tumor cell lines  Acceptable. • Biological mechanism of agent must be known before clinical study OR mechanism can be researched simultaneously with clinical trial?

  13. Discussion FDA Animal Rule: Compounds without clinical experience will follow FDA animal rule (one rodent species & one non-rodent specie) for toxicological and pharmacological testing?? • Funding options: • Use clinical samples from pre-existing clinical trial. • CCOP clinical trials and supplements.

More Related